FDA Approves Gedatolisib in Breast Cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

  • 1

    The FDA approved gedatolisib for adults with hormone receptor-positive, HER2-negative breast cancer after endocrine therapy progression.

  • 2

    Efficacy was evaluated in the VIKTORIA-1 trial, which enrolled 392 patients with advanced or metastatic breast cancer.

  • 3

    Median progression-free survival was 9.3 months for gedatolisib, fulvestrant, and palbociclib compared to 2.0 months for fulvestrant alone.

  • 4

    Objective response rates were 32% with the three-drug regimen and 28% with gedatolisib and fulvestrant, versus 1% with fulvestrant alone.

  • 5

    Warnings include stomatitis, dermatologic reactions, hyperglycemia, and embryo-fetal toxicity; the recommended dosage is 180 mg weekly.

Original Source(s)

FDA Approves Gedatolisib in Breast Cancer

  • by Kathryn Wighton

  • July 14, 2026

Related Content

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

PET/CT May Improve Detection of Local CRC Liver Metastasis Progression

The combined imaging approach improved detection of local recurrence and extrahepatic disease during early posttreatment follow‐up for colorectal liver metastases.